KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) Long-Term Investments (2019 - 2025)

Charles River Laboratories International has reported Long-Term Investments over the past 9 years, most recently at $207.0 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 5.21% year-over-year to $207.0 million; the TTM value through Dec 2025 reached $207.0 million, down 5.21%, while the annual FY2025 figure was $207.0 million, 5.21% down from the prior year.
  • Long-Term Investments for Q4 2025 was $207.0 million at Charles River Laboratories International, up from $194.6 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $218.4 million in Q4 2024 and troughed at $60.6 million in Q1 2022.
  • A 5-year average of $158.1 million and a median of $158.6 million in 2022 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: soared 189.5% in 2023 and later plummeted 37.25% in 2024.
  • Year by year, Long-Term Investments stood at $149.6 million in 2021, then increased by 22.02% to $182.6 million in 2022, then plummeted by 32.83% to $122.7 million in 2023, then skyrocketed by 78.02% to $218.4 million in 2024, then dropped by 5.21% to $207.0 million in 2025.
  • Business Quant data shows Long-Term Investments for CRL at $207.0 million in Q4 2025, $194.6 million in Q3 2025, and $216.1 million in Q2 2025.